Personalized Medicine in Nevada COBRE

内华达州 COBRE 的个性化医疗

• 批准号: 10458476
• 负责人: MARTIN R SCHILLER
• 金额: $ 213万
• 依托单位: UNIVERSITY OF NEVADA LAS VEGAS
• 依托单位国家: 美国
• 财政年份: 2018
• 资助国家: 美国
• 起止时间: 2018-06-01 至 2024-05-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10458476
• 关键词: Academic Medical Centers; Accreditation; Address; Advisory Committees; Algorithms; Applied Genetics; Award; Basic Science; Benchmarking; Big Data; Bioinformatics; Biomedical Research; Centers of Research Excellence; Clinical; Clinical Research; Clinical Services; Collaborations; Data; Data Analyses; Development; Diagnosis; Education; Environment; Etiology; Faculty; Fostering; Foundations; Funding; Future; Genetic; Genetic Counseling; Genetic Markers; Genetic Research; Genetic Services; Genome; Genomics; Goals; Grant; Graph; Growth; Healthcare; Human Genetics; Human Genome; Hybrids; Individual; Infrastructure; Institutes; Interdisciplinary Study; Investments; Leadership; Letters; Malignant Neoplasms; Marker Discovery; Measures; Medical; Medical Genetics; Medicine; Mentors; Microglia; Minority-Serving Institution; Modeling; Modernization; Monitor; Nevada; Outcome; Phase; Positioning Attribute; Principal Investigator; Private Sector; Privatization; Prognosis; Recording of previous events; Reference Values; Research; Research Infrastructure; Research Personnel; Research Project Grants; Research Support; Role; Schizophrenia; School Nursing; Societies; Students; Training; Translational Research; United States National Institutes of Health; Universities; base; career development; experience; genetic makeup; genetic technology; genome analysis; genome sequencing; genomic data; health care service organization; improved; individualized medicine; medical schools; novel; novel strategies; peer; personalized approach; personalized medicine; precision medicine; programs; psychosocial; role model; standard of care; statistics; success; synergism

ABSTRACT: OVERALL Society is progressing beyond “trial-and-error medicine” into a new data-driven era wherein one's genetic makeup is used to improve accuracy in medical diagnosis, prognosis, and treatment [1,2]. In President Barack Obama's State of the Union Address on January 20, 2015, he mentioned the promise of, and future investment in, personalized medicine. Many experts, including National Institutes of Health (NIH) Director Francis Collins, MD, believe that what is now called personalized, precision, or individualized medicine will transform the future of healthcare. As emerging genetic technologies gradually become the standard of care in some clinical settings, they will continue to improve, driven largely by academic medical centers. Modern genomic and associated bioinformatic analyses have become a staple of modern biomedical research. However, there is no COBRE in personalized medicine, despite its growing influence. The NIH COBRE program aims to strengthen the biomedical research infrastructure and improve competitive research in Institutional Development Award (IDeA)–eligible states. Modern genomic and bioinformatic analyses have become a staple of modern biomedical research. However, no COBRE exists in personalized medicine, despite its growing influence. UNLV is uniquely positioned to deliver on this urgent unmet need. The scientific premise of our COBRE is to advance the use of genomics and genetics in personalized medicine through cutting-edge research discovery and use of genetic markers, building a center of excellence that fosters new investigator independence, and collaborating with the UNLV School of Medicine and other partners in basic and translational research. Consistent with the goal of the NIH COBRE program i to strengthen biomedical research infrastructure and competitive research in IDeA eligible states, we propose three aims: (1) to build a sustained center in personalized medicine; (2) to nurture new investigator growth and independence; and (3) to grow personalized medicine research. To accomplish these goals our proposed COBRE consists of an Administrative core (AC), new Human Genome Data Algorithms to Analytics (HuGe DAtA) core and Genome Analysis and Sequencing Pipeline (GASP) cores, three new investigator research projects (RPs), a mentoring panel of internal and external experts, internal and external advisory committees, and a pilot grant program with 12 awards intended to cultivate a pipeline of new investigators. The leadership and mentoring teams have current research focused on the personalized medicine theme, steady NIH research funding, and a strong mentoring history. This COBRE will establish a foundation to launch medical genetics clinical services and a future educational program in clinical genetics through its collaboration with the UNLV School of Medicine, and through a collaborative educational program in genetic counseling in the School of Nursing. Similar outcomes were leveraged by previous COBRE programs. The major deliverables of the COBRE are RPs advancing personalized medicine, new independent investigators, a new biomedical research infrastructure, and a new program in personalized medicine. The sustainability model is built upon anticipated phase II funding, a pilot grant program, and research core sustainability hybrid models.

摘要：总体 社会正在超越“试用医学”到一个新的数据驱动时代，其中一个人的遗传 化妆用于提高医学诊断，预后和治疗的准确性[1,2]。在巴拉克总统 奥巴马在2015年1月20日发表的国际电联地址，提到了未来投资的承诺和未来的投资 在个性化医学中。许多专家，包括国立卫生研究院（NIH）董事弗朗西斯·柯林斯（Francis Collins） 医学博士，相信现在所谓的个性化，精度或个性化医学将改变未来 医疗保健。随着新兴遗传技术在某些临床上逐渐成为护理的标准 设置，它们将继续改善，主要由学术医疗中心驱动。现代基因组和 相关的生物信息学分析已成为现代生物医学研究的主食。但是，没有 个性化医学中的毛茸茸，使命其影响力不断增长。 NIH COBRE计划旨在加强 生物医学研究基础设施并改善机构发展奖的竞争性研究 （想法） - 符合条件的状态。现代基因组和生物信息学分析已成为现代的主食 生物医学研究。但是，个性化医学中没有毛cr，其影响力不断增长。 UNLV的独特位置可以满足这种紧急需求。我们毛绒的科学前提是 通过最先进的研究提高基因组和遗传学在个性化医学中的使用 发现和使用遗传标记，建立一个卓越的中心，培养新调查员 独立，并与UNLV医学院和基本和其他合作伙伴合作 翻译研究。与NIH COBRE计划I对强生物医学的目标一致 研究基础设施和符合思想国家的竞争性研究，我们提出了三个目标：（1）建立一个 在个性化医学中持续中心； （2）护理新研究者的成长和独立性； （3）到 发展个性化医学研究。为了实现这些目标，我们提出的cobre包括 行政核心（AC），新的人类基因组数据算法分析（巨大数据）核心和基因组 分析和测序管道（GASP）核心，三个新的研究者研究项目（RPS），一种心理 内部和外部专家，内部和外部咨询委员会以及试点赠款计划的小组 有12个奖项旨在培养新调查人员的管道。领导和心理团队有 当前的研究重点是个性化医学主题，稳定的NIH研究资金和强大的 指导历​​史。 这家圆锥将建立一个基础，以启动医疗遗传学临床服务和未来 通过与UNLV医学院的合作，临床遗传学教育计划， 通过护理学院的遗传咨询协作教育计划。类似的结果 被以前的毛线计划杠杆作用。毛绒的主要可交付成果是RPS前进 个性化医学，新的独立研究人员，新的生物医学研究基础设施和新的 个性化医学计划。可持续性模型建立在预期的II期资金基础上，试点 赠款计划和研究核心可持续性混合模型。

项目成果

Trends in osteoporosis and mean bone density among type 2 diabetes patients in the US from 2005 to 2014.

• DOI: 10.1038/s41598-021-83263-4
• 发表时间: 2021-02-12
• 期刊: Scientific reports
• 影响因子: 4.6
• 作者: Xu Y;Wu Q
• 通讯作者: Wu Q

Machine Learning Approaches for Fracture Risk Assessment: A Comparative Analysis of Genomic and Phenotypic Data in 5130 Older Men.

用于骨折风险评估的机器学习方法：5130 名老年男性基因组和表型数据的比较分析。

• DOI: 10.1007/s00223-020-00734-y
• 发表时间: 2020
• 期刊: Calcified tissue international
• 影响因子: 4.2
• 作者: Wu,Qing;Nasoz,Fatma;Jung,Jongyun;Bhattarai,Bibek;Han,MiraV
• 通讯作者: Han,MiraV

Genome-wide polygenic risk score for major osteoporotic fractures in postmenopausal women using associated single nucleotide polymorphisms.

• DOI: 10.1186/s12967-023-03974-2
• 发表时间: 2023-02-16
• 期刊: JOURNAL OF TRANSLATIONAL MEDICINE
• 影响因子: 7.4
• 作者: Wu, Qing;Jung, Jongyun
• 通讯作者: Jung, Jongyun

Bergamottin a CYP3A inhibitor found in grapefruit juice inhibits prostate cancer cell growth by downregulating androgen receptor signaling and promoting G0/G1 cell cycle block and apoptosis.

• DOI: 10.1371/journal.pone.0257984
• 发表时间: 2021
• 期刊: PloS one
• 影响因子: 3.7
• 作者: Vetrichelvan O;Gorjala P;Goodman O Jr;Mitra R
• 通讯作者: Mitra R

Genetic correlations between Alzheimer's disease and gut microbiome genera.

• DOI: 10.1038/s41598-023-31730-5
• 发表时间: 2023-03-31
• 期刊: SCIENTIFIC REPORTS
• 影响因子: 4.6
• 作者: Cammann, Davis;Lu, Yimei;Cummings, Melika J. J.;Zhang, Mark L. L.;Cue, Joan Manuel;Do, Jenifer;Ebersole, Jeffrey;Chen, Xiangning;Oh, Edwin C. C.;Cummings, Jeffrey L. L.;Chen, Jingchun
• 通讯作者: Chen, Jingchun